Alirocumab in Adult Patients With Hyperlipidemia After Liver Transplantation: A Short-term Observation

Abstract

Objective

To investigate the clinical efficacy of alirocumab in postoperative hyperlipidemia among liver transplant recipients.

Methods

We conducted a retrospective analysis of clinical data from liver transplant recipients with postoperative hyperlipidemia who received alirocumab treatment at our institution.

Results

Seventeen cases were observed, with a male-to-female ratio of 12:5. Patient ages ranged from 44 to 65 years, with an average age of 55.47 years. The initiation of alirocumab treatment occurred between 1 and 196 months postliver transplantation, averaging 44.88 months. Treatment duration was a minimum of 3 months. The levels of blood lipids were assessed at 4, 8, and 12 weeks during the treatment regimen. At 8 weeks, a statistically significant reduction in total cholesterol was recorded (P = .012), and this decrease was further pronounced at 12 weeks (P = .004). For LDL cholesterol, significant decreases were evident at 4 weeks (P = .011), 8 weeks (P = .005), and 12 weeks (P = .004). No significant changes were observed in high-density lipoprotein (HDL) cholesterol and triglyceride levels throughout the study period. In addition, all patients maintained stable liver function and immunosuppressant concentrations.

Conclusions

Alirocumab demonstrated a significant reduction in total cholesterol and low-density lipoprotein cholesterol levels among liver transplant recipients, with no observed increase in the risk of rejection. This suggests the potential effectiveness of alirocumab as a lipid-lowering therapy in liver transplant recipients.